127 related articles for article (PubMed ID: 14517211)
1. A defect in the p53 response pathway induced by de novo purine synthesis inhibition.
Bronder JL; Moran RG
J Biol Chem; 2003 Dec; 278(49):48861-71. PubMed ID: 14517211
[TBL] [Abstract][Full Text] [Related]
2. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
Bronder JL; Moran RG
Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
[TBL] [Abstract][Full Text] [Related]
3. An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint.
Zhang CC; Boritzki TJ; Jackson RC
Cancer Chemother Pharmacol; 1998; 41(3):223-8. PubMed ID: 9443639
[TBL] [Abstract][Full Text] [Related]
4. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.
Marsilje TH; Labroli MA; Hedrick MP; Jin Q; Desharnais J; Baker SJ; Gooljarsingh LT; Ramcharan J; Tavassoli A; Zhang Y; Wilson IA; Beardsley GP; Benkovic SJ; Boger DL
Bioorg Med Chem; 2002 Aug; 10(8):2739-49. PubMed ID: 12057663
[TBL] [Abstract][Full Text] [Related]
5. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
Sanghani SP; Moran RG
Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
[TBL] [Abstract][Full Text] [Related]
6. 10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylase.
Marsilje TH; Hedrick MP; Desharnais J; Capps K; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2003 Oct; 11(20):4503-9. PubMed ID: 13129586
[TBL] [Abstract][Full Text] [Related]
7. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
Moran RG; Baldwin SW; Taylor EC; Shih C
J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
Desharnais J; Hwang I; Zhang Y; Tavassoli A; Baboval J; Benkovic SJ; Wilson IA; Boger DL
Bioorg Med Chem; 2003 Oct; 11(20):4511-21. PubMed ID: 13129587
[TBL] [Abstract][Full Text] [Related]
9. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
[TBL] [Abstract][Full Text] [Related]
10. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of alpha- and gamma-carboxamide derivatives of 10-CF3CO-DDACTHF.
Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3587-92. PubMed ID: 15848771
[TBL] [Abstract][Full Text] [Related]
13. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.
Baldwin SW; Tse A; Gossett LS; Taylor EC; Rosowsky A; Shih C; Moran RG
Biochemistry; 1991 Feb; 30(7):1997-2006. PubMed ID: 1993209
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
Bulavin DV; Tararova ND; Aksenov ND; Pospelov VA; Pospelova TV
Oncogene; 1999 Oct; 18(41):5611-9. PubMed ID: 10523840
[TBL] [Abstract][Full Text] [Related]
15. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
[TBL] [Abstract][Full Text] [Related]
16. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
17. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
Beardsley GP; Moroson BA; Taylor EC; Moran RG
J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition.
Arima Y; Hirota T; Bronner C; Mousli M; Fujiwara T; Niwa S; Ishikawa H; Saya H
Genes Cells; 2004 Feb; 9(2):131-42. PubMed ID: 15009091
[TBL] [Abstract][Full Text] [Related]
19. The apo and ternary complex structures of a chemotherapeutic target: human glycinamide ribonucleotide transformylase.
Dahms TE; Sainz G; Giroux EL; Caperelli CA; Smith JL
Biochemistry; 2005 Jul; 44(29):9841-50. PubMed ID: 16026156
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
